Junfeng Chu News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Junfeng Chu. Real-time updates on events, politics, business and more.

Velcade and Rituxan Help Improve Responses in Marginal Zone Lymphoma

November 24, 2023

A treatment combination that includes Velcade and Rituxan helps improve responses and the safety profile in marginal zone lymphoma, according to a phase 2 trial.

Junfeng Chu Lymphoma Society Pharma Companies Pull Imbruvica Indication Marginal Zone Mantle Cell Lymphoma Cancer

Source: curetoday.com

Frontline VR-CAP Is Effective and Well Tolerated in MZL

October 23, 2023

Bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride generated robust responses with a tolerable safety profile when delivered as first-line therapy in patients with marginal zone lymphoma.

Bortezomib Velcade Junfeng Chu Follicular Lymphoma International Prognostic Index Doxorubicin Hydrochloride Nd Cytarabine Hydrochloride Patients With Marginal Zone Lymphoma

Source: onclive.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Junfeng Chu News Today

Velcade and Rituxan Help Improve Responses in Marginal Zone Lymphoma

Frontline VR-CAP Is Effective and Well Tolerated in MZL

Explore More Categories